Pharmaceutical Technology

MARCH 2, 2023

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. It provides ALPN-101 and ALPN-303 for the treatment of based immunotherapies and immune synapses to treat cancer and autoimmune and inflammatory diseases. The drug candidate is an engineered B-cell modulator.

Immunity 40

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 40

Express Pharma

JUNE 12, 2024

The investigational combination mRNA vaccine generated statistically significant higher immune responses in relation to the licensed comparator vaccines used in the randomised, observer-blind, active control study among 8,000 adults aged 50 years and older. Fluzone high-dose and Fluarix for influenza, and Spikevax for Covid-19.

Vaccines 104

Vaccines Adverse Reactions Immunity Immunization 104

European Pharmaceutical Review

NOVEMBER 23, 2023

Boehringer Ingelheim is acquiring Swiss biotech T3 Pharmaceuticals AG (T3 Pharma), for up to £406 million (450 million CHF), boosting its immuno-oncology portfolio. Overall, the process enables the design of immuno-oncology combination therapies in one single agent.

Immunity 115

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 115

pharmaphorum

JANUARY 18, 2021

In a document outlining the charges against Shafat Quadri, of North Potomac, Maryland the US Department of Justice (DoJ) referred only to “one of the largest pharmaceutical companies in the world” based in New Jersey.

Documentation 95

Documentation Immunity Immunization Pharmaceutical Companies 95

European Pharmaceutical Review

AUGUST 9, 2023

The pharmaceutical company announced that it plans to submit to global health authorities in 2024. appeared first on European Pharmaceutical Review. The REMIX data for Novartis’ novel BTK inhibitor will be presented at an upcoming medical meeting. There were 470 participants in the REMIX-1 study.

Immunity 94

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 94

pharmaphorum

FEBRUARY 9, 2022

The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment. Using a vaccine to utilise the patient’s own immune system to fight cancer is particularly attractive because of the targeted approach made possible by this technology. A broad front.

Vaccines 134

Vaccines Immunity Immunization Labelling 134

NY Times

JANUARY 2, 2021

The approvals, which include a shot developed by Bharat Biotech, an Indian pharmaceutical company, begin a vast campaign to inoculate the hard-hit nation’s 1.3 billion people.

Vaccines 98

Vaccines Pharmaceutical Companies Pharmaceutical Companies Immunity 98

pharmaphorum

JUNE 1, 2022

To try to improve health literacy, one study turned to VR to engage individuals and improve understanding of community immunity, or herd immunity, as it is also known. This has not escaped the notice of pharmaceutical companies looking to educate patients on topics, with which they may not have the most health literacy.

Vaccines 145

Vaccines Immunity Immunization Hospitals 145

European Pharmaceutical Review

APRIL 10, 2024

While this approach has shown to be safe and efficient in Clostridium difficile, the variability between donors may lead to random outcomes and responses in patients for immune-mediated diseases. Notably, from one donor to another, significant variations exist.

Immunity 95

Immunity Immunization Chemotherapy Diabetes 95

PharmaShots

APRIL 25, 2023

Numerous pharmaceutical companies have developed and authorized vaccines to provide immunity against COVID-19. Despite the drenched market of covid products, many other drugs have set an impressive benchmark for pharmaceutical companies in 2021.

Pharmaceutical Companies 56

Pharmaceutical Companies Pharmaceutical Companies Vaccines Immunity 56

Pharmaceutical Technology

SEPTEMBER 14, 2022

Most drugs available for the treatment of UC weaken patients’ immune systems, which puts them at higher risk of infection. Key opinion leaders (KOLs) interviewed by GlobalData have suggested that this group of patients would benefit from a greater number of treatment options that cause less systemic immune-related side effects.

Immunity 52

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 52

NY Times

APRIL 27, 2021

It feels very American to turn the vaccine rollout into a branding spectacle rooted in the worship of pharmaceutical companies.

Vaccines 62

Vaccines Pharmaceutical Companies Pharmaceutical Companies Immunity 62

European Pharmaceutical Review

NOVEMBER 9, 2023

TNF-alpha is an immune modulating cytokine whose dysregulation can lead to prolonged inflammatory responses and is known to drive disease in a range of autoimmune and inflammatory disorders. MYMD-1 has shown effectiveness in pre-clinical and clinical studies in regulating the immune system.

Drug Development 115

Drug Development Immunity Immunization Pharmaceutical Companies 115

Pharmaceutical Business Review

AUGUST 28, 2024

A fully human monoclonal antibody, Libtayo acts on the immune checkpoint receptor PD-1 on T cells. The company’s footprint spans 16 markets and employs over 12,000 individuals. It is said to be the first-line monotherapy approved for advanced non-small cell lung cancer (NSCLC).

Immunity 59

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 59

Pharmaceutical Technology

AUGUST 1, 2022

AMR occurs when disease-causing bacteria become resistant or immune to the antibiotics used to treat them. For this, it will be necessary for governments to establish substantial incentive schemes to encourage pharmaceutical companies to invest more time, effort and money into antibiotic research.

Vaccines 93

Vaccines Pharmaceutical Companies Pharmaceutical Companies Chemotherapy 93

Pharmaceutical Technology

MARCH 9, 2023

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.

Immunity 59

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 59

NY Times

NOVEMBER 10, 2021

The Secretary of State called for rich countries, pharmaceutical companies and others to “step up.”.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines Immunity 52

NY Times

JANUARY 7, 2021

Readers discuss an Op-Ed that argued that pharmaceutical companies don’t deserve the public relations lift from the rapid vaccine development.

Vaccines 52

Vaccines Pharmaceutical Companies Pharmaceutical Companies Immunity 52

pharmaphorum

NOVEMBER 2, 2020

Predicting protein structures would typically be a time-consuming process, but now scientists can use technology to better analyse viruses, thus helping in the search for a vaccine that can trigger an immune response. Scientists are using AI to sift through existing literature on a disease and study its disease’s structure.

Vaccines 132

Vaccines Drug Development Diabetes Immunity 132

pharmaphorum

OCTOBER 12, 2022

Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”. Forging an AI-enabled path toward precision medicine.

Drug Development 105

Drug Development Immunity Immunization Vaccines 105

pharmaphorum

SEPTEMBER 22, 2021

Some pharmaceutical companies, including Chiesi, established emergency committees to build business continuity plans and contingencies to protect drug supply and worker safety. Despite COVID-19, we expanded the new business unit to 275 employees in more than 20 countries in just 18 months.

Immunity 111

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 111

pharmaphorum

OCTOBER 21, 2022

Mukherjee explained that the human immune system becomes weaker as people age, which leads to a greater susceptibility to catching infectious diseases and also experiencing more acute cases when infected.

Vaccines 98

Vaccines Immunity Immunization Compounding 98

The Thyroid Pharmacist

OCTOBER 28, 2022

This irritation can interrupt the immune system’s ability to regulate itself, and put the body into a perpetual “attack mode” that is counterproductive to healing. Immune system health and gut health are linked. They can help improve digestion and nutrient extraction from the foods we eat, and can also balance the immune system.

Health and Personal Care Stores 105

Health and Personal Care Stores Immunity Immunization Grocery Stores 105

pharmaphorum

JUNE 8, 2021

At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home. All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. Chemotherapy still accounted for 72.6%

Chemotherapy 105

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunity 105

Pharmaceutical Technology

MARCH 9, 2023

Innovation S-curve for the pharmaceutical industry Monoclonal antibody drugs for cancer is a key innovation area in pharmaceutical Used to treat cancer, monoclonal antibodies are a type of targeted cancer therapy that use lab-created antibodies to find and kill specific cancer cells.

Immunity 52

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JANUARY 31, 2022

The digital transformation is allowing pharmaceutical companies to expand their drug discovery capabilities and accelerate drug development. As Shanaya says, some of the biggest developments have involved mRNA vaccines, “a completely different way to stimulate an immune response.”. Innovation at Pfizer.

Vaccines 97

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Development 97

pharmaphorum

AUGUST 27, 2020

Over the past five to ten years US investors have focused on technology and internet companies, and relatively little on new biotech or pharmaceutical companies. Conventional vaccines introduce an inactivated sample of a disease to patients with the aim of stimulating an immune response.

Vaccines 122

Vaccines Drug Pricing Compounding Immunity 122

Pharmaceutical Technology

FEBRUARY 26, 2023

Cue Biopharma overview Cue Biopharma operates as pharmaceutical company. The company develops biologic drugs for human immune system to treat cancers and autoimmune disorders. The company’s pipeline products include CUE-100 series to improve various tumor specific T cells Browse.

Immunity 40

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 40

Pharmaceutical Technology

FEBRUARY 26, 2023

Cue Biopharma overview Cue Biopharma operates as pharmaceutical company. The company develops biologic drugs for human immune system to treat cancers and autoimmune disorders. The company’s pipeline products include CUE-100 series to improve various tumor specific T cells Browse.

Immunity 40

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 40

pharmaphorum

MARCH 10, 2022

Driven by advancements in technology, these complex therapeutics have already made waves in life sciences, providing revolutionary treatment options in oncology, immune conditions and rare diseases. Biologics product development has increased steadily over the past decade, with the volume of business forecast to double by 2030.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Packaging Immunity 98

Pharmaceutical Technology

MARCH 1, 2023

Molecular Partners overview Molecular Partners is a clinical-stage bio-pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein-based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Drug Development Diabetes 40

Pharmaceutical Technology

MARCH 1, 2023

Molecular Partners overview Molecular Partners is a clinical-stage bio-pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein-based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Drug Development Diabetes 40

Pharmaceutical Technology

APRIL 18, 2023

HIV proteins or peptides are very immunogenic, and when utilised as experimental immunogens, they can elicit strong cellular and humoral immune reactions. A piece of an HIV protein, an epitope from an HIV protein, or a mixture of several HIV proteins or fragments of them can all act as the antigenic polypeptide and produce an immune response.

Mayo Clinic 59

Mayo Clinic Immunity Immunization Vaccines 59

pharmaphorum

SEPTEMBER 20, 2022

The two companies have been talking to each other since 2017 and formally working together since 2019, when Pfizer started using CytoReason’s biological models in research aimed at developing new drugs for immune-mediated diseases and cancer immunotherapies.

Drug Development 52

Drug Development Immunity Immunization Pharmaceutical Companies 52

Pharmaceutical Technology

MAY 8, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. J&J develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products.

Vaccines 96

Vaccines Immunity Immunization Pharmaceutical Companies 96

European Pharmaceutical Review

AUGUST 14, 2023

Swedish pharmaceutical company Vicore Pharma is developing treatments for diseases where the angiotensin II type 2 receptor (AT2R) has a central role in stopping and reversing disease pathology and where there is a large unmet medical need. The company’s lead candidate, C21, is an angiotensin II type 2 receptor agonist (ATRAG).

Labelling 98

Labelling Immunity Immunization Pharmaceutical Companies 98

The Thyroid Pharmacist

NOVEMBER 29, 2023

The truth is that most supplement companies do not undergo the same scrutiny and testing that pharmaceutical products do, because many of the tests which are required of pharmaceutical companies are voluntary for supplement companies. We have 290 expiring in April 2025.)

Health and Personal Care Stores 73

Health and Personal Care Stores Immunity Immunization Labelling 73